Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels.
Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases.
Our focus is on developing drugs to treat cancer including novel, small molecule immuno-oncology agents.
Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases.
Our focus is on developing drugs to treat cancer including novel, small molecule immuno-oncology agents.
Total raised: $145.1M
Founded date: 2012
Investors 1
| Date | Name | Website |
| - | The Column... | thecolumng... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 12.03.2020 | - | $120M | - |
| 22.05.2014 | Series B | $25.1M | - |
Mentions in press and media 7
| Date | Title | Description |
| 25.11.2021 | TCG Announces the Addition of TCG iPartners | TCG’s iPartners represents a new ideation advisory group comprised of leading academic investigators and biotech entrepreneurs. Working closely with TCG’s Swanson Fellows and our core investment team, this group is dedicated to crafting inn... |
| 13.03.2020 | After Kymera's raise, Nurix nabs $120M as it too hones in on clinical work | Sanofi- and Gilead Sciences-backed Nurix Therapeutics is following suit with rival biotech Kymera in raising a major cash haul for its protein modulation R&D work. Sponsored by Agilent Technologies How would you like to win free bench s... |
| 22.05.2014 | Nurix Raises $25.1M in Series B Financing | Nurix, Inc., a San Francisco, California-based company that discovers and develops therapies that modulate the ubiquitin proteasome system (UPS), raised $25.1m in Series B financing. Backers included Third Rock Ventures and The Column Group... |
| 22.05.2014 | Nurix Lands $25.1M in Series B financing | SAN FRANCISCO, CA, Nurix has raised $25.1 million Series B financing. >> Click here for more funding data on Nurix >> To export Nurix funding data to PDF and Excel, click here Third Rock Ventures and The Column Group toda... |
| 04.04.2013 | Stealthy biotech raises $5.3M for T-cell-specific immunosuppressants for autoimmune diseases | Formed in 2009 as Kura Therapeutics, the company appears to be led by Tim Kutzkey, a partner at The Column Group, and Mark Goldsmith, a partner at Third Rock. It first raised a $3.1 million round raised last year. Promoted Telemedicine’s po... |
| - | The Column Group Raises a $725 Million Fourth Fund | The Column Group (TCG), a biotech venture capital firm focused on building innovative drug discovery companies, announced the closing of The Column Group IV (TCG IV) and its related investment vehicles totaling $725 million. With TCG IV, th... |
| - | Stealthy biotech raises $5.3M for T-cell-specific immunosuppressants for autoimmune diseases | Another early stage California company in stealth mode has garnered a round of financing. This time it’s a biotech company called Nurix Inc., founded by three University of California, San Francisco and University of California, Berkeley re... |